SARS-CoV-2 Neutralizing Antibodies with Defined Variable Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing SARS-CoV-2 neutralizing antibodies lack a standardized technique for measuring neutralizing ability, making it difficult to compare efficacy and identify superior antibodies, and there are concerns about side effects, immunogenicity, and cross-reaction when administered to humans.
Innovation Solution
Development of specific antibodies or fragments with defined heavy and light chain variable regions, including specific amino acid sequences, that inhibit the binding between the SARS-CoV-2 spike protein and ACE2, thereby preventing infection, and a pharmaceutical composition comprising these antibodies for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different methods and conditions are used for neutralization tests, then various antibody candidates can be evaluated, but the measurement results cannot be compared and it is difficult to identify superior antibodies
Solution Approach 1:
The patent standardizes the neutralization test by fixing key parameters including virus type (SARS-CoV-2), antibody concentration range (0.001-10 μg/mL), incubation conditions (37°C, 1 hour), and cell line (Vero E6). This parameter standardization allows consistent measurement of neutralization ability across different antibody candidates while maintaining evaluation versatility.
2Reliability
If a large number of antibodies are produced and screened through trial and error, then superior neutralizing antibodies can be identified, but the development time and complexity increase
Solution Approach 1:
The patent performs preliminary screening of antibody candidates using standardized neutralization tests before advancing to animal experiments and clinical trials. This preliminary action filters out ineffective candidates early, reducing the number of antibodies that require further complex evaluation and accelerating the identification of superior neutralizing antibodies.
3Reliability
If antibody drugs are administered to humans, then therapeutic effects can be achieved, but side effects, immunogenicity, and cross-reaction risks remain
Solution Approach 1:
The patent conducts comprehensive safety evaluations including animal experiments and immunogenicity assessments before human administration. This beforehand cushioning identifies and mitigates potential side effects, immunogenicity risks, and cross-reaction concerns prior to clinical use, protecting human subjects while enabling therapeutic application.
Data Source
AI summary
An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.